Neuren Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NURPF research report →
About the company
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes.
- CEO
- Jonathan Charles Pilcher
- IPO
- 2009
- Employees
- 8
- HQ
- Camberwell, VIC, AU
Price Chart
- Market Cap
- $1.71B
- P/E
- 69.75
- P/S
- 32.83
- P/B
- 6.26
- EV/EBITDA
- 96.07
- Div Yield
- 0.00%
- Gross Margin
- 76.93%
- Op Margin
- 11.03%
- Net Margin
- 47.09%
- ROE
- 9.20%
- ROIC
- 1.65%
- Revenue
- $64.61M · -70.20%
- Net Income
- $30.42M · -78.58%
- EPS
- $0.24 · -77.98%
- Op Income
- $22.02M
- FCF YoY
- 1211.13%
- 52W High
- $14.80
- 52W Low
- $7.70
- 50D MA
- $9.12
- 200D MA
- $10.73
- Beta
- 1.62
- Avg Volume
- 72
Get TickerSpark's AI analysis on NURPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NURPF coverage
Recent articles, reports, and earnings notes.
No research on NURPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NURPF report →Similar companies
Peers in the same neighborhood.